Tesamorelin

Batch #344910Batch #344910
Report #53458Report #53458
Tested at 1.82mgTested at 1.82mg
Size: 2mg
Visa Mastercard American Express Discover Apple Pay Google Pay
Ships by ...
Flag
FREE Shipping

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About Tesamorelin

Tesamorelin is a synthetic peptide that has been studied for its role in stimulating pathways associated with growth hormone release. Research has explored its potential applications in areas such as metabolic regulation cellular signaling and mechanisms related to tissue composition and maintenance. Its properties have made it a focus of interest in studies involving physiological and biochemical processes.

Product Specifications

Tesamorelin Lyophilized Powder in 3ml vial.

Application

Research peptide evaluated in visceral fat studies.

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C221H366N72O67S

PubChem CID

16137828

CAS Number

218949-48-5

Molecular Weight

5135.89 g/mol

Synonyms

TH9507

Storage

Store at ≤6°C, sealed, away from heat, light, and moisture.

Tesamorelin Research

1. Clinical Overview 

Tesamorelin is a laboratory-made version of a natural hormone that encourages the body to release growth hormone. It is administered as a daily injection under the skin with a standard dosage of 2mg. The drug may also increase natural growth hormone levels and reduce deep belly fat (visceral fat).

Tesamorelin was developed for people with H.I.V. who develop additional abdominal fat because of their antiretroviral drugs. In large clinical studies, it did reliably reduce visceral fat, and it has been officially approved for that purpose. New England Journal of Medicine+1

 

2. Key Human Findings  

Tesamorelin were tested in two major clinical trials of HIV patients taking antiretroviral therapy (ART) with excess abdominal fat. Each test ran for 26 weeks, with an additional 26 weeks of safety checks. When measured, Tesamorelin decreased deep belly fat (visceral fat) by a ratio of about 15–20% versus a placebo. Waist size, as well how patients felt about their body shape, also got better.

When patients were treated for up to 52 weeks, the reduction in fat was sustained. But the fat returned slowly when they stopped taking Tesamorelin. The typical dose for these studies was 2 mg administered as a subcutaneous injection once a day PubMed+2PubMed+2

A later study in people with HIV found that Tesamorelin also helped reduce some liver fat and improve liver health markers in those showing signs of nonalcoholic fatty liver disease (NAFLD).

Overall, Tesamorelin’s main benefit is reducing harmful deep belly fat (visceral fat), not causing general weight loss. JAMA Network+1

 

3. Safety & Metabolic Effects   

Tesamorelin was well tolerated in clinical trials. (the most common side effects were mild skin reactions at the injection site.) A slight elevation of IGF-1 was noted and to be taken as normal. Doctors advise checking blood sugar because some patients experienced temporary spikes in fasting glucose or mild glucose intolerance, even though most studies didn’t find serious long-term problems.

Longer-term use (up to 52 weeks) found that Tesamorelin had a continued effect on deep belly fat (VAT), without major side effects, though usually the fat came back once treatment was discontinued. Regulators recommend monitoring for high blood sugar (hyperglycemia) and not using it in people with active cancer. FDA Access Data+2NATAP+2

 

4. Overview   

The standard clinical dose in the trials is 2 mg subcutaneously daily. Tesamorelin reduces visceral (abdominal) fat significantly in HIV-infected patients with lipodystrophy and may improve body shape and related quality-of-life measures during the treatment continuation. Liver fat and metabolic parameters modestly respond in a variable manner. Safety monitoring should include blood glucose measurement, and the benefits generally disappear after treatment is discontinued, so it is a treatment for on-therapy management of excess visceral fat rather than a permanent cure. England Journal of Medicine+1

 

4. References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in HIV lipodystrophy. NEJM. 2007. New England Journal of Medicine 

  2. Falutz J, et al. Pooled analysis of two phase-3 trials of tesamorelin in ART-treated HIV patients. (Phase-3 pooled analysis). 2010. PubMed 

  3. FDA Clinical review and approval history — Egrifta (tesamorelin) for injection; approval and safety warnings (label / risk review). FDA Access Data+1 

  4. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV. JAMA. 2014. JAMA Network 



You ask,
we answer.